After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line. Sectoral indices ended the day mixed, with stocks in the realty sector and stocks in the pharma sector leading the losses, while stocks in the PSU sector gained the most.
At the closing bell, the BSE Sensex stood lower by 232 points (down 0.7%) and the NSE Nifty closed down by 80 points (down 0.8%). The BSE Mid Cap index ended the day down 1.6%, while the BSE Small Cap index ended the day down by 2.2%.
Asian stock markets finished in green. As of the most recent closing prices, the Hang Seng was down by 0.6% and the Shanghai Composite was up by 0.7%. The Nikkei 225 was up by 0.4%. Meanwhile, European markets, were trading mixed. The FTSE 100 was up by 0.8%, The DAX, was down by 0.2% while the CAC 40 was up by 0.7%.
The rupee was trading at Rs 68.09 against the US$ in the afternoon session. Oil prices were trading at US$ 78.75 at the time of writing.
In the news from commodity markets. Crude oil prices are in focus today as they are trading newar four-year highs. Last Thursday, Brent crude oil prices shot above US$ 80 a barrel. This is the highest level since 2014. In the past one year alone, oil prices have surged more than 50%.
Notably, this has influenced domestic fuel prices as well. With petrol and diesel prices across the country hitting all-time high levels.
Rising crude not only affects fuel prices in India but could threaten India's economic recovery.
As we wrote in a recent edition of The 5 Minute WrapUp...
You can read the entire article here.
Richa Agarwal, editor of Hidden Treasure, tracks the oil and gas sector very closely. This is what she had to say about rising crude prices:
She believes it is a bearish sign for stock markets globally. At the same time, any market correction, will throw up interesting buying opportunities in small-cap stocks.
This is what she said...
Note that crude oil prices have been witnessing a rising trend of late.
However, this is not good news from India's perspective.
Back home inflation seems to be on a downward trajectory, however rising crude prices could be a threat.
As per the data released by the government, retail inflation cooled to a five-month low of 4.28% in March following a decline in food prices including vegetables. The inflation based on Consumer Price Index (CPI) was 4.44% in February.
The inflation remained above the Reserve Bank of India's (RBI) medium-term target, supporting views that monetary policy is likely to remain unchanged at the next review in early June.
The RBI, which has kept rates steady since a cut of 25 basis points in August last year, is widely expected to maintain rates at their current level in the next review due on 6 June.
How this pans out remains to be seen. We will keep you updated on all the developments from this space.
Moving on to news from stocks in the pharma sector. Glenmark Pharma share price was in focus today after it was reported that the company received a ANDA (abbreviated new drug application) approval from the United States Food & Drug Administration (USFDA) for Colesevelam Hydrochloride tablets.
The drug is a generic version of Daiichi Sankyo's Welchol tablets, and is indicated for treatment of cholesterol.
According to IQVIA sales data, the Welchol tablets had annual sales of around US$520 million in the US.
Notably, Glenmark's current portfolio consists of 135 products authorised for distribution in the US market and 62 abbreviated new drug applications (ANDAs) pending approval with the USFDA.
Glenmark Pharma share price ended the day down by 0.5%.
Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.
However, note that USFDA alerts on Indian pharma companies have increased over the past few years. Regulators used to visit the plants every two years. Now they come every eight months. Increasing inspections have led to a total of 41 import alerts in the past eight years - 33 of them (80%) in just the last four years (2013-16). This clearly signifies increased USFDA scrutiny on Indian pharma firms. If that wasn't enough, increasing pricing pressure in the generics segment has dented realisations.
However, the recent development of USFDA expediting the drug approval process can bring some respite for Indian pharma companies. This comes as drug approvals for Indian companies have gone up 50% in the period from January to June 2017 compared to the same period last year.
While short-term pain is expected, companies with strong R&D capabilities and compliant plants will do well over the long term. The uncertainties make it important to be stock specific in the sector. It is important to look for companies that have the competence and staying power to overcome the challenges.
Pharma stocks ended the day lower by 2.6%.
For information on how to pick stocks that have the potential to deliver big returns, download our special report now!
Read the latest Market Commentary
Equitymaster requests your view! Post a comment on "Sensex Extends Losses; Pharma Stocks Top Losers". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!